الفهرس | Only 14 pages are availabe for public view |
Abstract Panretinal photocoagulation is a well-known principal therapy for proliferative diabetic retinopathy. Although PRP reduces the possibility of severe visual loss, it has several side effects, such as macular edema, constricted visual field and laserinduced vitreous hemorrhage. Also, additional laser therapy or surgical intervention has been necessary after PRP performance. Recent reports have shown that VEGF plays a key role in neovascularization of the eye, and that intravitreal anti-VEGF injection can lead to regression of neovessels. Anti-VEGF is effective when PRP is not possible; also when neovascular glaucoma develops after full PRP. However, we experienced unfavorable adverse events after injection of bevacizumab. Both PRP alone and bevacizimab augmented PRP are effective in regression of neovessels with no evident difference in BCVA , size of neovessels or central macular thickness over 12 week follow up period except that bevacizumab augmented PRP gives faster effect in decreasing the size of neovessels however this effect is short term. Therefore, intravitreal bevacizumab injection may be performed with caution until its long- term effects and safety are confirmed in future. |